Today: 21 March 2026
Subscribe

Michał Rogucki

IonQ stock jumps nearly 22% after results; 2026 revenue outlook and SkyWater deal in focus

IonQ stock jumps nearly 22% after results; 2026 revenue outlook and SkyWater deal in focus

IonQ shares jumped 21.7% to $40.88 after reporting fourth-quarter revenue of $61.9 million and a 2026 forecast above expectations. Trading volume reached 66.4 million shares. The company aims for an operational 256-qubit system by late 2026 and announced quantum-secured links in Romania. Wall Street targets diverged, with price estimates ranging from $35 to $100.
27 February 2026
···
Intel stock price: INTC set for a tense open after SambaNova AI deal, as chip nerves linger

Intel stock price: INTC set for a tense open after SambaNova AI deal, as chip nerves linger

Intel shares fell 3% to $45.46 Thursday, breaking a two-day gain, as chip stocks slid following Nvidia’s drop despite strong results. Intel and SambaNova announced a multi-year AI-inference partnership, with Intel Capital joining SambaNova’s $350 million funding round. Kevin O’Buckley, head of Intel Foundry Services, is leaving for Qualcomm. Investors await U.S. inflation data Friday amid ongoing volatility in tech stocks.
27 February 2026
····
Plug Power stock slides in premarket after $132.5 million Project Gateway sale deal

Plug Power stock slides in premarket after $132.5 million Project Gateway sale deal

Plug Power shares fell 0.5% to $1.90 premarket Friday after announcing a deal to sell its Project Gateway site in New York to Stream Data Centers for at least $132.5 million. The sale, which could reach $142 million depending on conditions, is set to close by June 30, 2026, pending regulatory and contractual approvals. Plug closed Thursday at $1.91. The company’s next earnings report is due March 2.
27 February 2026
·
EOSE stock: Eos Energy slips again premarket after brutal earnings selloff and softer 2026 outlook

EOSE stock: Eos Energy slips again premarket after brutal earnings selloff and softer 2026 outlook

Eos Energy shares fell 2.5% premarket Friday after a 39.4% drop Thursday, trading at $6.57. The company reported record Q4 revenue of $58 million but posted a $120.5 million quarterly net loss and set 2026 revenue guidance below consensus. Roth Capital cut its price target, citing execution risks. Eos said “substantial doubt” about its ability to continue as a going concern no longer exists.
27 February 2026
···
AXS leadership reshuffle: Julie Lamb made chief talent officer, Jason Boxer promoted to CFO

AXS leadership reshuffle: Julie Lamb made chief talent officer, Jason Boxer promoted to CFO

AXS promoted Julie Lamb to chief talent officer and Jason Boxer to chief financial officer, both reporting to CEO Bryan Perez. The moves come after recent appointments in technology and innovation leadership. Lamb and Boxer previously held senior vice president roles. AXS provides ticketing for over 1,600 sports and entertainment brands, including the LA28 Olympics and Coachella.
27 February 2026
CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics stock whipsaws again as takeover talk resurfaces — here’s what to watch

CRISPR Therapeutics shares fell 1.9% to $60.55 in premarket trading Friday after an 11.85% surge Thursday on renewed takeover speculation flagged by Betaville, The Fly reported. The company reported $116 million in 2025 Casgevy revenue and ended the year with $1.98 billion in cash. Management is set to appear at investor conferences starting March 2.
27 February 2026
···
Dutch Bros stock (BROS) cools in premarket after a 6% pop — here’s what traders watch next

Dutch Bros stock (BROS) cools in premarket after a 6% pop — here’s what traders watch next

Dutch Bros shares fell 0.4% to $53.69 in premarket trading Friday after closing up 6.0% on Thursday. The stock has gained about 14% over three sessions. Investors are awaiting U.S. producer price data at 8:30 a.m. ET, which could impact rate expectations and growth stock valuations. Dutch Bros recently reported Q4 revenue up 29.4% to $443.6 million and forecast 2026 revenue near $2 billion.
27 February 2026
·
Zscaler stock slides 9% premarket after results; higher spend spooks traders

Zscaler stock slides 9% premarket after results; higher spend spooks traders

Zscaler shares dropped 8.6% to $152.99 in premarket trading after reporting a wider quarterly GAAP loss despite a 26% revenue increase and raised guidance. The company cited higher sales and R&D costs and flagged cautious IT spending on large deals. Annual recurring revenue rose 25% to $3.36 billion. Zscaler forecast April-quarter revenue of $834 million to $836 million.
27 February 2026
···
Paramount Skydance (PSKY) stock price pops in premarket as Netflix steps aside on Warner Bros deal

Paramount Skydance (PSKY) stock price pops in premarket as Netflix steps aside on Warner Bros deal

Paramount Skydance shares jumped 9.5% to $12.24 in premarket trading Friday after Netflix declined to match its $31-per-share bid for Warner Bros Discovery. California’s attorney general said the deal faces an open investigation, and analysts warned of possible regulatory challenges. Paramount’s offer includes a $7 billion termination fee and a ticking fee if closing is delayed past September 2026.
27 February 2026
···
Haleon PLC stock ticks up after earnings whiplash; here’s what matters for HLN shares

Haleon PLC stock ticks up after earnings whiplash; here’s what matters for HLN shares

Haleon shares rose 1% to 398.2 pence in early London trading Friday after sharp swings earlier in the week. The company reported 2025 revenue of £11.03 billion and forecast 3%-5% organic revenue growth for 2026, with a £500 million buyback planned. CEO Brian McNamara said U.S. growth is expected to return this year. Haleon’s next trading update is due April 29.
27 February 2026
··
GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

GSK share price today: stock edges up after Japan and China reviews, plus $950 million 35Pharma deal

GSK shares rose 0.74% to 2,183 pence by 0855 GMT after Japan and China accepted regulatory filings for two experimental liver-disease drugs. The company also agreed to buy Canada’s 35Pharma for $950 million, adding a pulmonary hypertension asset. GSK closed down 2.12% the previous session. Investors await first-quarter results on April 29.
27 February 2026
··
1 … 18 19 20 21 22 … 27

Stock Market Today

  • Novavax (NVAX) Stock Falls 1.23% Amid Upcoming Earnings Report
    March 20, 2026, 7:08 PM EDT. Novavax (NVAX) shares closed at $9.62, down 1.23%, outperforming the broader market declines as the S&P 500 fell 1.51%. Over the past month, Novavax gained 5.58%, surpassing the Medical sector's 7.54% loss. Investors await the company's financial results, expecting a substantial earnings per share (EPS) decline of 110.58% year-over-year to -$0.31 and revenues forecasted to fall 91.63% to $55.78 million. Full-year estimates also show significant drops. Despite this, the Zacks Consensus EPS estimate recently rose 47.68%, leading to a Zacks Rank of #3 (Hold) for Novavax. The Medical - Biomedical and Genetics industry ranks in the bottom 42% of all industries, reflecting sector challenges. Market watchers are advised to monitor updates closely as Novavax navigates these headwinds.
Go toTop